Samalin Investment Counsel’s Novavax NVAX Stock Holding History

Samalin Investment Counsel’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-25	Closed	–	–	402
2019 Q4	$0	Buy	+25	New	+$108	﹤0.01%	552

Other funds holding NVAX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Samalin Investment Counsel's NVAX Position: Q1 2020 in Review

Samalin Investment Counsel sold out of Novavax (NVAX) in Q1 2020, closing a stake of 25 shares.

Samalin Investment Counsel first reported a position in NVAX in Q4 2019 and held it in 1 quarter. The position peaked at $0 in Q4 2019. 117 funds tracked by Wall St. Rank hold NVAX as of Q1 2020.

Samalin Investment Counsel reported no remaining Novavax position as of Q1 2020 after selling out during the quarter.
Samalin Investment Counsel sold 25 Novavax shares in Q1 2020.
Samalin Investment Counsel first reported a position in Novavax in Q4 2019 and held it in 1 quarter.
Samalin Investment Counsel's Novavax position peaked at $0 in Q4 2019.
117 funds tracked by Wall St. Rank held Novavax as of Q1 2020.

Based on Samalin Investment Counsel's 13F filing for Q1 2020, filed 4 May 2020.